Biome Australia Limited (ASX:BIO)

Revenue by Segment

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019
Innovative Evidence-Based Products Linking the Gut and Human Health	18.42M	13.01M	7.24M	4.12M	2.32M
Innovative Evidence-Based Products Linking the Gut and Human Health Growth	41.57%	79.79%	75.52%	77.81%	178.40%
Total	18.42M	13.01M	7.24M	4.12M	2.32M
Total Growth	41.57%	79.79%	75.52%	77.81%	178.40%

Revenue by Geography

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019
Australia	16.93M	12.11M	6.78M	3.82M	2.06M
Australia Growth	39.75%	78.79%	77.39%	85.25%	147.60%
International	1.49M	894.42K	459.74K	293.23K	245.03K
International Growth	66.22%	94.55%	56.78%	19.67%	-
Unallocated	-	-	-	9.51K	11.51K
Unallocated Growth	-	-	-	-17.36%	-
Total	18.42M	13.01M	7.24M	4.12M	2.32M
Total Growth	41.57%	79.79%	75.52%	77.81%	178.40%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 15, 2026

Data Sources Report a data error